Business Context and Reporting Period
Company: The Clorox Company (CLX)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended December 31, 2025 (Fiscal Year 2026 Q2)
Business Overview: A leading multinational manufacturer of consumer and professional products including cleaning, disinfecting, food, water filtration, and personal care brands. The company operates through four reportable segments: Health and Wellness, Household, Lifestyle, and International.
Key Financial Metrics
| Metric (in millions, except per share) | 3 Months Ended 12/31/2025 | 6 Months Ended 12/31/2025 |
|---|---|---|
| Net Sales | $1,673 | $3,102 |
| Gross Profit | $722 | $1,318 |
| Gross Margin | 43.2% | 42.5% |
| Net Earnings (Attributable to Clorox) | $157 | $237 |
| Diluted EPS | $1.29 | $1.93 |
| Operating Cash Flow | N/A | $404 |
| Cash and Equivalents | $227 | $227 |
| Total Debt (Current + Long-term) | $2,793 | $2,793 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 1% year-over-year (YoY) for the quarter and 10% for the six-month period. The six-month decline was driven by lower shipments following incremental ERP-related shipments in the prior year's Q4 and the divestiture of the Better Health VMS business.
- Profitability Pressure: Diluted EPS fell 16% for the quarter and 18% for the six-month period. Gross margin compressed 60 basis points (bps) for the quarter and 230 bps for the six-month period due to higher manufacturing and logistics costs.
- Segment Performance:
- Health and Wellness: Sales up 2% (quarter) but down 9% (six months); EBIT down 27% (six months) due to lower sales and higher costs.
- Household: Sales down 6% (quarter) and 13% (six months); EBIT down 54% (quarter) and 55% (six months) driven by lower consumption and unfavorable price mix.
- Lifestyle: Sales down 5% (quarter) and 14% (six months); EBIT up 3% (quarter) due to lower advertising spend.
- International: Sales up 7% (quarter) and 3% (six months); EBIT up 48% (quarter) driven by strong Latin American shipments and favorable FX.
- One-Time Items: The prior year included a $118 million loss on the divestiture of the Better Health VMS business and significant insurance recoveries ($23 million net benefit in the prior quarter) related to the 2023 cyberattack, which are not present in the current period.
Outlook, Risks, and Unusual Items
- Strategic Transactions:
- GOJO Acquisition: On January 22, 2026, Clorox announced a definitive agreement to acquire GOJO Industries for approximately $2,250 million in cash, expected to close before the end of fiscal 2026. Funding will be primarily through debt.
- P&G Venture Buyout: The venture agreement for the Glad business expired January 31, 2026. Clorox agreed to purchase P&G's 20% interest for $476 million, payable in Q3 FY2026.
- Transformation Costs: The company is in the stabilization phase of its ERP transition. Total incremental transformational investment is expected to be approximately $580 million. Current period included $17 million (quarter) and $49 million (six months) in digital capabilities and productivity enhancement costs.
- Liquidity Position: Current liabilities exceeded current assets by $619 million as of December 31, 2025, primarily due to the $476 million P&G venture obligation classified as current. Management maintains a $1,200 million revolving credit facility with no borrowings outstanding.
- Risks: Macroeconomic volatility, inflationary headwinds, supply chain disruptions, and potential impacts of new U.S. trade policies/tariffs. The company also faces integration risks related to the pending GOJO acquisition.
Investor Verification Checklist
- Debt Capacity: Verify the impact of the $2.25 billion GOJO acquisition on leverage ratios and credit rating stability, given the current debt load of ~$2.8 billion.
- Margin Recovery: Monitor whether gross margin compression stabilizes as the company absorbs higher manufacturing/logistics costs and completes the ERP transition.
- Volume Trends: Assess if the 9% volume decline in the six-month period is a temporary result of ERP shipment timing or a structural shift in consumer demand.
- Working Capital: Review the $619 million current liability gap and the timing of the $476 million P&G payment to ensure liquidity remains sufficient for operations and the GOJO deal.
- Non-GAAP Adjustments: Scrutinize the "Digital capabilities and productivity enhancements investment" ($49 million for six months) to understand the duration and total cost of the transformation program.